Gilead Sciences, Inc. (NasdaqGS:GILD) is looking for M&A. Daniel P. O'Day, Chairman and Chief Executive Officer said, "We're in a very good position as we look at our M&A strategy for the future because of the richness of our portfolio and the level of investment that we need to continue to do to realize the potential in the portfolio. We can be selective about M&A given the M&A that we've done over the past several years, and we will be. But of course, we'll continue to look at that in our business.

And our capital allocation strategy will remain the same, which is, first and foremost, to invest in the promising pipeline for the benefit of patients and the medicines that are newly launched and established for our patient communities around the world. Secondly, look at M&A and partnerships that will complement with the strategy that I mentioned before".